Corient Private Wealth LLC Trims Stake in Repligen Co. (NASDAQ:RGEN)

Corient Private Wealth LLC lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 11.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,281 shares of the biotechnology company’s stock after selling 405 shares during the period. Corient Private Wealth LLC’s holdings in Repligen were worth $472,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in RGEN. Resources Management Corp CT ADV purchased a new position in Repligen in the third quarter worth $37,000. Quarry LP boosted its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares in the last quarter. UMB Bank n.a. increased its position in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Global Retirement Partners LLC raised its holdings in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC purchased a new position in shares of Repligen during the 4th quarter valued at about $58,000. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $133.41 on Friday. Repligen Co. has a one year low of $113.50 and a one year high of $184.98. The company has a 50-day simple moving average of $154.21 and a two-hundred day simple moving average of $148.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $7.49 billion, a PE ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Evercore ISI initiated coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Finally, TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of “Hold” and an average target price of $178.64.

Insider Activity at Repligen

In other news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.20% of the stock is currently owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.